Identification of novel inhibitor targeting Fyn kinase using molecular docking analysis

Dharani Nedunchezhian1, Kulanthaivel Langeswaran2* & Sundar Santhoshkumar3

1Department of Biotechnology and Bioinformatics, Bishop Heber College, Bharathidasan University, Tiruchirapalli, Tamil Nadu, India; 2Cancer Genetics & Molecular Biology Laboratory, Department of Bioinformatics, Science Campus, Alagappa University, Karaikudi, Tamil Nadu, India; 3Department of Computer Science, Science Campus, Alagappa University, Karaikudi, Tamil Nadu, India; Dr. V. K. Langeswaran - Email: dr.langeswaran@gmail.com; *Corresponding author

Received May 21, 2019; Accepted June 3, 2019; Published June 15, 2019

DOI: 10.6026/97320630015419

Abstract:
Identification of tyrosine Fyn kinase inhibitor is recognized as an effective and feasible therapeutic measure in reducing consequences of memory loss disorder Alzheimer’s. The present investigation has been attempted with an objective to find out a novel potent inhibitor with similar homologous structure to Fyn kinase using structure based in silico screening measure. Such derived structure was compared with natural data base pool and were systematically analyzed. Ligand based interaction was also tested and evaluated. We applied a molecular dynamic simulation technique to validate the stability of the identified complexes and to understand the ligand binding mechanism. Results provide information on the characteristics of novel and potent inhibitor for tyrosinase Fyn kinase protein so as to develop an innovative strategy to treat AD.

Keywords: Tyrosine fyn kinase, ligand binding, dynamic simulation

Background:
Tyrosine Fyn Kinase is a determined protein factor involved in the activity of cell signaling pathway. Unusual occurrence in the rate of activity of Fyn Kinase in signaling, render toxic substances, resulting chronic disorder such as Alzheimer’s [1]. This played a crucial role in phosphorylation and anti-phosphorylation process and confers its intra molecular affinity [2]. Cell adhesion, synaptic activity and signaling [3]. Several earlier reports were demonstrated and evident that Tyrosine Fyn was recognized as driven force causing AD by interacting Amyloid B and Tau, conferring a novel therapeutic strategy to address and minimize the consequences of AD. Regulation of Fyn activity was obviously studied in several types of signaling pathways [4]. Shirazi et al. [5] have reported that Fyn Protein showed immune reactivity while unusual phosphorylated Tau protein. However, several studies were focused on inter linkage of Tyrosine Fyn Kinase protein with AD. Participation of Fyn Kinase Protein in inducing and act as causative agent for chronic disorder. Therefore, it received more attention on its ability in signaling pathways. Advancement of docking based virtual screening technique in accordance with affinity of protein and ligand conferring an ideal way for screening the lead novel compounds in the field of molecular docking [6]. Identification of macromolecules and validity was the remarkable factor in targeting the drugs, however, it is still unclear and debatable [7]. Therefore, in the present investigation, a trial has been taken up (i) to predict the novel potent inhibitor targeting Fyn Kinase and (ii) to identify the ligand by comparing natural database and (iii) to explore protein ligand complex stability and its behavior.
Materials and Methods:
Using Software packages such as CPU platforms performed aforementioned tasks. Stipulations were CPU-Supermicro 32Gb Nvidia Quadro K620 with 2GB included, LLC, 2019 Desmond. Fyn protein complex code (PDB ID 1DQ7) with a resolution of 2.8 Å. Optimization of Hydrogen bond was employed and rely on clusters of hydrogen-bonded species were selectively optimized. Minimizing the structure has been performed to refine the structure, with a restrained minimization. The RMSD value of the atom was minimized. The partial atomic charges were also computed and analyzed.

The generated structure of a prepared protein shown in an order such as receptor, site, constraints and rotatable groups. Receptor is a workspace and the ligand were identified as a molecule. The green color marker should be shown after the ligand molecule is picked in the workspace. Van der Waals (vdW) radius scaling of 14 for closely contacts with the ligand and the receptor (a protein molecule) is used. Scale factor default value is 0.30 and the partial charge cut off default value is 0.25. Scaling of van der Waals radii was performed on the non-polar atoms. Scale factor default value is 1.0 as the contact by small gaps in the solvent-exposed regions and also determines where in the scoring grids are located. Energetic program was used to analyses spectrum to predict the modes of the protein ligand complexes. Workflow filtering method was used. It was also evaluated the acceptability of analogues based on Lipinski’s rule of 5 which was essential to ensure the drug-like properties of the molecules were assessed. GSA coplexed with compounds from Zinc-NPD, NPB, Nci-NPD database was employed by using the Desmond modular. In this present study, totally three from Zinc-NPD, NPB, Nci-NPD database (144027, 2455, 9219) were chosen, theses three are the top leads from each database identified based on the docking score. All these three complexes were simulated for 10 analyzed deviations (RMSF) and considered as backbone of the protein. The RMSF was assessed to estimate fluctuation.

Table 1: Virtual screening of ZINC-NPD, NPB and NCI results

| S.No | Natural compound | LDS | GE | VDW | COUL | GEM |
|------|-----------------|-----|----|-----|------|-----|
| 1    | ZINC-NPD        | -16.372 | -68.639 | -37.652 | -30.987 | -121.633 |
| 2    | 144027          | -15.884 | -62.871 | -46.541 | -36.330 | -113.640 |
| 3    | 128794          | -15.848 | -90.119 | -58.883 | -31.236 | -130.885 |
| 4    | 2582            | -15.812 | -79.583 | -52.157 | -27.227 | -105.107 |
| 5    | 118082          | -15.799 | -82.457 | -55.718 | -26.739 | -99.998 |

Table 2: ADME results of the top compounds

| S. No | COMPOUND | MW  | DONAR HB | ACCEPT HB | % HOA | Q plogPfo/W | Q plogHERG | QPP Caco | QPPMDCK |
|-------|----------|-----|----------|-----------|-------|-------------|-------------|--------|---------|
| 01    | ZINC-NPD144027 | 396.463 | 1        | 9        | 88.588 | -5.76       | -5.708     | 0.235  | 0.059   |
| 02    | NPB-2455     | 240.238 | 3        | 2.25     | 86.594 | 2.038       | -4.643     | 463.328 | 215.385 |
| 03    | NCI-9129     | 478.636 | 1        | 10.5     | 83.564 | 2.919       | -5.399     | 209.104 | 128.805 |

(ZINC-NPD, NPB, NCI) Natural compound database; DS-Docking energy; GE- Glide energy; GEVDE-VDE, GECOUL-COUL; GEMODE-GEM.
Figure 1: Interaction profile and docking pose of the best hit compounds obtained from screening for FYN 2DQ7 with Zinc NPD(a, b), NPB(c, d), NCI-NPD(e, f) databases.
Result and Discussion:
In the present study high throughput virtual screening (HTPS) method was used to identify potential molecule inhibitors using compounds obtained from pharmacophore against active FYN kinase protein of the ligands were further docked flexibly by XP which generates compounds were tabulated in Table 1 and shown in Figure 1. Drug likeness was tested and followed by Quikprop method of Schrodinger ADME properties of identified inhibitors were recorded systematically and tabulated (Table 1) based on Lipiski’s rule of 5 [8]. Results of the docking indicated that efficient inhibitors identified among three database, chief lead compound was found to be G Plog Po and was promising alternate.

Final results of screened compounds were selected data base as an input to find matches to hypothesis to screen the best ligands molecules. In earlier studies, virtual screening molecules against several proteins related to human disorder were reported. Poli et al. [9] have demonstrated that few efficient Fyn inhibitors have identified and proved to be blocked the activities of Fyn kinase.In our study, three different Natural compounds databases were chosen namely ZINC NPD (3,76,884 Ligand molecules), NPB (20,783 Ligand molecules), NCI(56,000 Ligand molecules) were taken for screening process. Based on the docking score top three compounds were selected from each database.
Analysis on ADME of inhibitors:
ADME properties evaluation of identified chief compound. A Plogpo scored highest range (Table 2). It was observed that identified compounds with a group of hydrogen bonding donor and acceptor pair as found. This present study results were matching the findings of Zhu [10]. The biological membrane access ranges were found to be range from 293.11 to 2288.96 and the range of QPMDCK was 96.8 to 100 [11]. Thomas et al. [12] have established that improvement in ADME properties of identified compounds are attributed and translate to the pharmacokinetic properties. Findings were correlated with earlier study results. In the present investigation, two ligands from the ZINC-NPD database (95914724, 2455) and NCI-NPD database (6152) were chosen. 95914724, 2455, 6152 were the top lead identified based on docking score. All two complexes were calculated and analyzed RMED value in order to evaluate deviation in the structure during simulation (RMSD). The stability of protein-ligand (2DQ7-144027, 2DQ7- 2455, 2DQ7-9219) complexes is shown. Figure 2 that the deviations and fluctuations were not observed much and hence the results were agreeable. These results inferred that the compounds have slight fluctuations, which are observed, only in the loop region of the target protein. Zinc complexes in lead molecules may contribute and involved in coordination if neurons characterized by fast ligand exchange [13]. In the present study, it was evident that interaction of compound with zinc was attributed to the selected ligand and it was agreement with our findings [14]. The results of the RMSD plot reported that high scored lead compound could be satisfactorily explored in the present simulation experiment.

Conclusion:
We are interested identifying the inhibitors targeting the Fyn kinase for the treatment of Alzheimer’s disease. It was concluded that Fyn kinase inhibitors are, therefore promising novel molecules and in disrupting a neurodegenerative disorder. Computational studies such as receptor based screening and molecular dynamics simulation have proved and supported our claims to be the useful tool and the best ligand to block the Fyn kinase. This study has confirmed that these compounds can be a potent inhibitor to block the interactions between the targets and inhibit the progression of Alzheimer’s disease.

Acknowledgement:
The article has been written with the financial support of RUSA - phase 2.0 grant sanctioned vide Letter No.F.24-51/2014-U policy (TNMulti – Gen), Dept of Edn. Govt of India Dt, 09.10.2018.

Conflict of Interest
The authors declared that there are no conflicts of interest.

References
[1] Poli G et al. J Chem Inf Model. 2013 53:2538. [PMID: 24001328]
[2] Krämer-Albers EM et al. Cell Mol Life Sci. 2011 68: 2003 [PMID: 21207100]
[3] Resh MD. Int J Biochem Cell Biol. 1998 30:1159.[PMID: 9839441]
[4] Hu JL et al. Mol Brain. 2010 3:20. [PMID: 20569495]
[5] Shirazi SK et al. Neuroreport. 1993 4:435. [PMID: 8388744]
[6] Nguyen TH et al. J Biol Chem. 2002 277:24274. [PMID: 11983687]
[7] Moellering RE et al. Nature 2009 462:182. [PMID: 19907488]
[8] Lipinski CA et al. Adv Drug Deliv Rev. 2001 46:3. [PMID: 11259830]
[9] Goldsmith JF et al. Biochem Biophys Res Commun. 2002298:501. [PMID: 12408980]
[10] Zhu L et al. Mol Divers. 2018 22:979. [PMID: 30083853]
[11] Thomas SM et al. Annu Rev Cell Dev Biol. 199713:513. [PMID: 9442882]
[12] Thomas R et al. Pediatrics. 2015 135; e994. [PMID: 25733754]
[13] Elena Attriá-Blasco et al. Dalton Trans. 2017 46: 12750. [PMID: 28424538]
[14] Monika et al. Bioinformation 2013 9: 583. [PMID: 23888100]

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Edited by P. Kangueane

Citation: Nedunchezhiyan et al. Bioinformation 15(6): 419-424 (2019)
